News

An injection of IONIS-MAPTRx resulted in a 70 percent decrease in tau protein produced in the brains of non-human primates, researchers at  Ionis Pharmaceuticals, the potential treatment’s maker, are reporting. These positive pre-clinical findings helped in the design of a first clinical study, now underway and enrolling, that will…

Long-term exposure to caffeine worsens Alzheimer’s disease symptoms, a new mouse study shows. The study “Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal Aging” was published in the journal Frontiers in Pharmacology. Alzheimer’s disease is characterized…

Betanin, the compound that gives beets their distinctive red color, can help slow the accumulation of misfolded proteins in the brain, a process that is associated with Alzheimer’s disease. The study, “Beeting” Alzheimer’s: Inhibition of Cu2+-β-amyloid mediated oxidation and peroxidation by betanin from sugar beets,” was a…

Spanish regulators have signed off on Oryzon Genomics’ plan to conduct a Phase 2 clinical trial of its Alzheimer’s therapy ORY-2001. The ETHERAL trial, which will cover patients with mild to moderate forms of the disease, will be the first to assess the effectiveness of an epigenetic therapy for Alzheimer’s. This approach…

The brain works in a coordinated matter, like a tuned orchestra, scientists say. If a single instrument is out of sync, it affects the entire ensemble. In Alzheimer’s disease, damage to certain nerve cells is sufficient to alter brainwave rhythms and cause a loss of cognitive function. A new mouse study shows how…

The transportation service Lyft is teaming up with the Global Alzheimer’s Platform Foundation to help those who are participating in an Alzheimer’s trial get to and from U.S. and Canadian research sites. Under the agreement, Lyft will provide transportation for those taking part in Eli Lilly’s Phase 2 TRAILBLAZER-ALZ (NCT03367403) trial and their…

A form of vitamin B3 was found to prevent brain damage and improve memory and physical function in a new mouse model of Alzheimer’s disease, suggesting a possible new target for treatment. Mice given ChromaDex’s Niagen (nicotinamide riboside, or NR) — a unique member of the vitamin B3 family…

Cognition Therapeutics’ lead investigative therapy Elayta (CT1812) shows promise in improving the activity of brain cells in patients with Alzheimer’s disease, according to the results of a Phase 1b/2a trial. Elayta is a small molecule that displaces amyloid-beta oligomers formed in Alzheimer’s disease from their binding sites, or…

The total cost to care for people living with Alzheimer’s disease and other dementias is projected to surpass a quarter of a trillion dollars in 2018 for the second consecutive year, according to a report from the Alzheimer’s Association. The organization’s recently released 2018 Alzheimer’s Disease Facts and…

Investigational therapy Neflamapimod led to significant improvements in episodic memory function in patients with early Alzheimer’s disease, results from EIP Pharma’s Phase 2a clinical trial show. “Significant unmet need exists for improved Alzheimer’s treatments which is why we are so encouraged…